Risk assessment for aflatoxin: an evaluation based on the multistage model.
Lifetime cancer potency of aflatoxin was assessed based on the Yeh et al. study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available information for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a biologically motivated risk assessment model. The best estimate of aflatoxin potency was 9 (mg/kg/day)-1 for individuals negative for hepatitis B and 230 (mg/kg/day)-1 for individuals positive for hepatitis B.
Bowers
J
J
U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Washington, D.C. 20204.
Brown
B
B
Springer
J
J
Tollefson
L
L
Lorentzen
R
R
Henry
S
S
D000328:Adult; D000348:Aflatoxins / Q000008:administration & dosage / Q000009:adverse effects*; D003043:Cocarcinogenesis; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008954:Models, Biological; D012306:Risk; D014481:United States / Q000453:epidemiology
D000348:Aflatoxins